Filing Flows › Impact Biomedical (IBO) › Q3 2025
Impact Biomedical (IBO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Impact Biomedical (IBO) reported revenue of $18K for the third quarter 2025 (Q3 2025) and +157% from the quarter before.
Impact Biomedical, Q3 2025: revenue $18K, net loss $1.5M, operating cash flow −$613K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18K | +157% | — |
| Operating profit | −$948K | — | — |
| Net earnings | −$1.5M | — | — |
| Operating cash flow | −$613K | — | — |
What changed
Revenue was $18K in Q3 2025, up 157% from the previous quarter.
Operating costs exceeded revenue by $948K, an operating margin of -5266.7%. The quarter ended with a net loss of $1.5M, narrower than the previous quarter's $14.4M loss. Minority interests bore $5K of it: to shareholders the quarter was a loss of $1.5M.
Operating cash flow was −$613K. Non-cash charges added back $288K of depreciation and amortization and $1K of share-based compensation. Working capital and other items added $573K.
Questions
What was Impact Biomedical's revenue in the third quarter 2025?
Impact Biomedical (IBO) reported revenue of $18K for the third quarter 2025 (Q3 2025) and +157% from the quarter before.
Source: Impact Biomedical 10-Q on SEC EDGAR.